FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Apr. 8, 2013-- MEDNAX, Inc., (NYSE: MD) today announced the acquisition of Neonatology Associates, Ltd. (NAL), a neonatal physician group practice based in Phoenix, Arizona. The practice will become part of MEDNAX’s Pediatrix Medical Group division.

NAL is a private practice that consists of 24 neonatologists, 5 pediatric hospitalists, 39 advanced practitioners, and 35 other clinical and administrative support staff who provide a wide spectrum of services, including neonatal intensive care, labor and delivery, and hearing screen services, at 27 hospitals throughout Central and Northern Arizona and in Tucson.

The practice, which has served the area for more than 40 years, performs approximately 38,000 newborn hearing screens annually and its annual NICU patient volume is approximately 60,000 days. NAL has been a leader in neonatal education through conference and training programs and several of the practice’s clinicians have been involved in research programs and clinical trials.

“We are confident that partnering with such an established leader in the industry will further advance the specialized and critical services we have provided to the community's newborn babies for more than four decades," said Ravi Gunawardene, M.D., who will serve as medical director for the practice. “In an evolving, uncertain and complex healthcare environment, this partnership will support our infrastructure, provide collaborative research and education, and ultimately enhance the ability of our physicians to focus on patient care.”

Pediatrix Medical Group, through its affiliated entities, is an established provider of a full spectrum of services including neonatology, maternal-fetal, pediatric cardiology, pediatric and OB/GYN hospitalist, developmental pediatric and newborn hearing screen services at locations throughout the state of Arizona.

The practice was acquired for cash and the transaction is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

ABOUT MEDNAX

MEDNAX, Inc. is a national medical group that comprises the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a division of MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 330 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric critical care physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. In 2007, MEDNAX expanded into anesthesia services. Today, American Anesthesiology includes more than 1,475 anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 2,100 physicians in 34 states and Puerto Rico. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and assessments made by MEDNAX’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well MEDNAX’s current reports on Form 8-K, filed with the Securities and Exchange Commission.

Source: MEDNAX, Inc.

MEDNAX, Inc.
David T. Parker, 954-384-0175, x 5300
Vice President, Investor Relations & Corporate Communications
david_parker@mednax.com